Ian D. Plumb
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Ian D. Plumb has a total of 354 co-authors. Here are the top co-authors by number of shared publications:
- Karisa K. Harland
Department of Emergency Medicine University of Iowa Health Care Iowa City Iowa USA
5 shared publications Anusha Krishnadasan
Olive View-and Ronald Reagan University of California Los Angeles Medical Center , Los Angeles, California , USA
4 shared publications- Melissa Briggs-Hagen
COVID‐19 Response Team Centers for Disease Control and Prevention (CDC) Atlanta Georgia USA
4 shared publications Michael G. Bruce
Centers for Disease Control & Prevention, United States
4 shared publications- David A. Talan
Olive View–UCLA Education and Research Institute and the David Geffen School of Medicine, Department of Emergency Medicine, University of California , Los Angeles, California
3 shared publications - Ghinwa Dumyati
New York Emerging Infections Program, University of Rochester Medical Center , Rochester, New York
3 shared publications
Latest Publications
- 20 July 2026
- Published by Oxford University Press (OUP) in Journal of the Pediatric Infectious Diseases Society
- Vol. 15 (8)
Household Transmission of SARS-CoV-2 in Washington and Oregon, United States, 2022-2024
Background: Households remain high-risk settings for SARS-CoV-2 transmission. Identifying contemporaneous risk factors for infection among household contacts of an index case can guide public health strategies. Methods: We conducted a prospective observational household study in Oregon and Washington, USA, during 2022-2024. Participants completed enrollment, weekly, and follow-up symptom surveys and submitted sera and weekly nasal swabs. Swabs were tested for SARS-CoV-2 by polymerase chain reaction (PCR) ; a subset of positive specimens underwent whole genome sequencing. Sera was tested for SARS-CoV-2 antibodies. We evaluated individual and household-level factors associated with risk of SARS-CoV-2 infection after 1-14 days (likely secondary infection) among household contacts within households with a distinct (ie, single) index case. Results: Overall, we identified 617 households with a distinct index case, of which 46% were children. The estimated secondary infection rate was 16% (95% CI 13.6%, 18.8%), reflecting 203 secondary infections among 1267 household contacts. Among household contacts, factors associated with secondary infection included low anti-nucleocapsid antibody titers (RR: 1.88, 95% CI 1.34, 2.64), or residing with an index case who was symptomatic (RR: 1.85; 95% CI 1.04, 3.23), or had viral detection >1 week (RR: 2.15, 95% CI 1.55, 2.97). Among 136 sequenced index-secondary case pairs, 128 (94%) shared SARS-CoV-2 lineages. Conclusion: During 2022-2024, 1 in 7 household contacts of index cases were infected within two weeks, with higher rates in contacts with lower antibody levels and when index cases had symptoms or longer viral detection. These findings can inform ongoing strategies to mitigate SARS-CoV-2 community transmission.
- 20 July 2026
- Published by Oxford University Press (OUP) in Journal of the Pediatric Infectious Diseases Society
- Vol. 15 (8)
Household Transmission of SARS-CoV-2 in Washington and Oregon, United States, 2022-2024
Background: Households remain high-risk settings for SARS-CoV-2 transmission. Identifying contemporaneous risk factors for infection among household contacts of an index case can guide public health strategies. Methods: We conducted a prospective observational household study in Oregon and Washington, USA, during 2022-2024. Participants completed enrollment, weekly, and follow-up symptom surveys and submitted sera and weekly nasal swabs. Swabs were tested for SARS-CoV-2 by polymerase chain reaction (PCR) ; a subset of positive specimens underwent whole genome sequencing. Sera was tested for SARS-CoV-2 antibodies. We evaluated individual and household-level factors associated with risk of SARS-CoV-2 infection after 1-14 days (likely secondary infection) among household contacts within households with a distinct (ie, single) index case. Results: Overall, we identified 617 households with a distinct index case, of which 46% were children. The estimated secondary infection rate was 16% (95% CI 13.6%, 18.8%), reflecting 203 secondary infections among 1267 household contacts. Among household contacts, factors associated with secondary infection included low anti-nucleocapsid antibody titers (RR: 1.88, 95% CI 1.34, 2.64), or residing with an index case who was symptomatic (RR: 1.85; 95% CI 1.04, 3.23), or had viral detection >1 week (RR: 2.15, 95% CI 1.55, 2.97). Among 136 sequenced index-secondary case pairs, 128 (94%) shared SARS-CoV-2 lineages. Conclusion: During 2022-2024, 1 in 7 household contacts of index cases were infected within two weeks, with higher rates in contacts with lower antibody levels and when index cases had symptoms or longer viral detection. These findings can inform ongoing strategies to mitigate SARS-CoV-2 community transmission.
- 21 October 2025
- Published by Wolters Kluwer Health in Journal of Occupational and Environmental Medicine
- Vol. 68 (3) , e245-e251
Differential Odds of COVID-19 Infection Associated With Household and Workplace Exposures in US Health Care Personnel
Objective: The aim of the study was to evaluate associations between occupational and nonoccupational COVID-19 exposures, household characteristics, and COVID-19 infection risk among health care personnel (HCP). Methods: This is a nested analysis of HCP enrolled in a multisite vaccine effectiveness study. COVID-19 infection was confirmed through source documentation. Exposures and household characteristics were self-reported. Results: HCP with household COVID-19 exposure had significantly higher infection odds, while workplace exposure was associated with decreased odds of infection. No associations were observed for community exposures, living with children, or living with unvaccinated household members. Conclusions: Household exposure posed greater COVID-19 risk to HCP unlike exposures in the workplace. Combined with demonstrated vaccine effectiveness, these findings suggest that workplace infection control measures were successful, while interventions targeting household transmission may be critical for protecting HCP.
- 21 October 2025
- Published by Wolters Kluwer Health in Journal of Occupational and Environmental Medicine
- Vol. 68 (3) , e245-e251
Differential Odds of COVID-19 Infection Associated With Household and Workplace Exposures in US Health Care Personnel
Objective: The aim of the study was to evaluate associations between occupational and nonoccupational COVID-19 exposures, household characteristics, and COVID-19 infection risk among health care personnel (HCP). Methods: This is a nested analysis of HCP enrolled in a multisite vaccine effectiveness study. COVID-19 infection was confirmed through source documentation. Exposures and household characteristics were self-reported. Results: HCP with household COVID-19 exposure had significantly higher infection odds, while workplace exposure was associated with decreased odds of infection. No associations were observed for community exposures, living with children, or living with unvaccinated household members. Conclusions: Household exposure posed greater COVID-19 risk to HCP unlike exposures in the workplace. Combined with demonstrated vaccine effectiveness, these findings suggest that workplace infection control measures were successful, while interventions targeting household transmission may be critical for protecting HCP.
- 29 May 2025
- Published by Oxford University Press (OUP) in Journal of Travel Medicine
- Vol. 32 (6)
Efficacy of bismuth subsalicylate on the prevention of travellers′ diarrhoea, 2018–2023
Background: Travellers’ diarrhoea (TD) is the most common travel-related illness. Bismuth subsalicylate (BSS) is indicated for the treatment of TD. BSS is also used off-label for the prevention of TD, based on studies from the 1980s indicating TD protection; however, these studies have limitations. The objective of this study was to determine the efficacy of BSS in the prevention of TD. Methods: This study was a prospective, double-blinded, placebo-controlled, randomized clinical trial (NCT03535272) with two arms: BSS 4 tablets twice daily (2.1 grams of BSS total) vs placebo. Travellers were included if they were ≥ 18 and < 70 years of age at the time of enrollment, were leaving for an international trip ≥7 days after their pretravel consultation, travelling in country for ≥7 days but ≤ 21 days, and travelling to either Southeast Asia, South Central Asia, North Africa, or Sub-Saharan Africa. Self-completed web-based questionnaires were administered before, during, and after travel. Results: 270 participants were included. The median age was 32 years (Interquartile range [IQR]: 27–44); 63% were female. Travellers were most frequently White (144; 61%) and non-Hispanic (239; 94%). The most frequent country of travel was Kenya (n = 87; 32%). The median total trip duration was 10 days ([IQR]: 8–13). The most frequent reason for travel was leisure/tourism (230, 85%). There was no significant difference among the groups for symptoms of loose stool and/or diarrhoea, although target sample size was not reached. Conclusions: This study provides the first new data since the 1980s about the potential use of BSS in the prevention of TD. These data should not be viewed as evidence in isolation because of sample size constraints; further studies are needed to determine if there is a benefit in certain traveller groups or under certain circumstances.
- 29 May 2025
- Published by Oxford University Press (OUP) in Journal of Travel Medicine
- Vol. 32 (6)
Efficacy of bismuth subsalicylate on the prevention of travellers′ diarrhoea, 2018–2023
Background: Travellers’ diarrhoea (TD) is the most common travel-related illness. Bismuth subsalicylate (BSS) is indicated for the treatment of TD. BSS is also used off-label for the prevention of TD, based on studies from the 1980s indicating TD protection; however, these studies have limitations. The objective of this study was to determine the efficacy of BSS in the prevention of TD. Methods: This study was a prospective, double-blinded, placebo-controlled, randomized clinical trial (NCT03535272) with two arms: BSS 4 tablets twice daily (2.1 grams of BSS total) vs placebo. Travellers were included if they were ≥ 18 and < 70 years of age at the time of enrollment, were leaving for an international trip ≥7 days after their pretravel consultation, travelling in country for ≥7 days but ≤ 21 days, and travelling to either Southeast Asia, South Central Asia, North Africa, or Sub-Saharan Africa. Self-completed web-based questionnaires were administered before, during, and after travel. Results: 270 participants were included. The median age was 32 years (Interquartile range [IQR]: 27–44); 63% were female. Travellers were most frequently White (144; 61%) and non-Hispanic (239; 94%). The most frequent country of travel was Kenya (n = 87; 32%). The median total trip duration was 10 days ([IQR]: 8–13). The most frequent reason for travel was leisure/tourism (230, 85%). There was no significant difference among the groups for symptoms of loose stool and/or diarrhoea, although target sample size was not reached. Conclusions: This study provides the first new data since the 1980s about the potential use of BSS in the prevention of TD. These data should not be viewed as evidence in isolation because of sample size constraints; further studies are needed to determine if there is a benefit in certain traveller groups or under certain circumstances.
- Open Access
- 27 May 2025
- Published by Elsevier in IJID Regions
- Vol. 16, 100676
SARS-CoV-2 secondary attack rates and risks for transmission among agricultural workers and their households in Guatemala, 2022-2023
- 27 May 2025
- Published by Elsevier in IJID Regions
- Vol. 16, 100676
Open AccessSARS-CoV-2 secondary attack rates and risks for transmission among agricultural workers and their households in Guatemala, 2022-2023
- 26 March 2025
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 12 (5) , ofaf185
Coronavirus Disease 2019 Symptoms by Immunity Status and Predominant-Variant Period Among US Blood Donors
Background: Amid changing variant and immunity landscapes since early in the coronavirus disease 2019 (COVID-19) pandemic, common COVID-19 symptoms need better understanding in relation to prior immunity or infecting variant. Methods: American Red Cross blood donors were surveyed during February–April 2022 about prior COVID-19 vaccinations and symptomatic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections. Donations were tested for anti-nucleocapsid antibodies to inform infection history. Restricting analysis to donors with survey-reported infections during the Omicron BA.1-predominant period (19 December 2021 through 19 March 2022), we used multivariable logistic regression to compare symptoms by existing immunity from prior infection or vaccination. Restricting analysis to those with no existing immunity, we compared symptoms by variant-predominant period of their first reported infection (BA.1 vs before). Results: Among 9505 donors with a BA.1-predominant period infection, donors with prior infection (n = 1115), vaccination (n = 5888), or both (n = 1738) were less likely than those without prior immunity (n = 764) to report loss of taste or smell, lower respiratory tract, constitutional, or gastrointestinal symptoms and more likely to report upper respiratory tract symptoms. Stronger associations followed recent prior infection, vaccination, or more vaccine doses. Among 8539 donors without prior immunity, those with survey-reported infections during the BA.1-predominant period (n = 764) were less likely to report loss of taste or smell, or lower respiratory tract symptoms than those with infections before this period (n = 7775). Conclusions: Our data suggest that both prior immunity and Omicron predominance redistributed COVID-19 symptoms toward upper respiratory tract presentations and likely both contributed to a decrease in COVID-19 severity over time. These findings may better inform COVID-19 identification in high-immunity settings and demonstrate additional benefits of vaccination.
- 26 March 2025
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 12 (5) , ofaf185
Coronavirus Disease 2019 Symptoms by Immunity Status and Predominant-Variant Period Among US Blood Donors
Background: Amid changing variant and immunity landscapes since early in the coronavirus disease 2019 (COVID-19) pandemic, common COVID-19 symptoms need better understanding in relation to prior immunity or infecting variant. Methods: American Red Cross blood donors were surveyed during February–April 2022 about prior COVID-19 vaccinations and symptomatic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections. Donations were tested for anti-nucleocapsid antibodies to inform infection history. Restricting analysis to donors with survey-reported infections during the Omicron BA.1-predominant period (19 December 2021 through 19 March 2022), we used multivariable logistic regression to compare symptoms by existing immunity from prior infection or vaccination. Restricting analysis to those with no existing immunity, we compared symptoms by variant-predominant period of their first reported infection (BA.1 vs before). Results: Among 9505 donors with a BA.1-predominant period infection, donors with prior infection (n = 1115), vaccination (n = 5888), or both (n = 1738) were less likely than those without prior immunity (n = 764) to report loss of taste or smell, lower respiratory tract, constitutional, or gastrointestinal symptoms and more likely to report upper respiratory tract symptoms. Stronger associations followed recent prior infection, vaccination, or more vaccine doses. Among 8539 donors without prior immunity, those with survey-reported infections during the BA.1-predominant period (n = 764) were less likely to report loss of taste or smell, or lower respiratory tract symptoms than those with infections before this period (n = 7775). Conclusions: Our data suggest that both prior immunity and Omicron predominance redistributed COVID-19 symptoms toward upper respiratory tract presentations and likely both contributed to a decrease in COVID-19 severity over time. These findings may better inform COVID-19 identification in high-immunity settings and demonstrate additional benefits of vaccination.
- Open Access
- 25 September 2024
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 11 (10) , ofae545
Symptoms Six Weeks After COVID-19 Are Reduced Among US Health Care Personnel Receiving Additional Vaccine Doses During the Omicron Period, December 2021–April 2022
Background: The objective of this study was to test the hypothesis that subsequent doses of the coronavirus disease 2019 (COVID-19) vaccine are associated with lower incidence of COVID-19-like symptoms at 6 weeks after infection. Methods: This study was a case–control analysis of health care personnel in an ongoing multicenter COVID-19 vaccine effectiveness study. We enrolled participants at the time of COVID-19-like symptoms between December 19, 2021, and April 27, 2022, which corresponded to the early Omicron-predominant period after original monovalent severe acute respiratory syndrome coronavirus 2 additional vaccination doses became available. Our outcome was self-reported symptoms completed 6 weeks after the onset of symptoms. Results: We enrolled 2478 participants, of whom 1422 (57%) had COVID-19. The prevalence of symptoms at 6 weeks was 26% (n = 373) in those with COVID-19 and 18% (n = 195) in those without COVID-19. Fatigue (11%) and difficulty sleeping (7%) were most strongly associated with COVID-19. A total of 1643 (66%) participants received a subsequent vaccine dose (after the primary series). Participants with COVID-19 who had received a subsequent vaccination had lower odds of symptoms at 6 weeks (adjusted odds ratio [aOR], 0.55; 95% CI, 0.43–0.70), but this relationship was not observed in those without COVID-19 (aOR, 0.87; 95% CI, 0.59–1.29). Conclusions: Health care personnel who received subsequent doses of original monovalent COVID-19 vaccine had a lower prevalence of symptoms at 6 weeks than those that did not.
- 25 September 2024
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 11 (10) , ofae545
Open AccessSymptoms Six Weeks After COVID-19 Are Reduced Among US Health Care Personnel Receiving Additional Vaccine Doses During the Omicron Period, December 2021–April 2022
Background: The objective of this study was to test the hypothesis that subsequent doses of the coronavirus disease 2019 (COVID-19) vaccine are associated with lower incidence of COVID-19-like symptoms at 6 weeks after infection. Methods: This study was a case–control analysis of health care personnel in an ongoing multicenter COVID-19 vaccine effectiveness study. We enrolled participants at the time of COVID-19-like symptoms between December 19, 2021, and April 27, 2022, which corresponded to the early Omicron-predominant period after original monovalent severe acute respiratory syndrome coronavirus 2 additional vaccination doses became available. Our outcome was self-reported symptoms completed 6 weeks after the onset of symptoms. Results: We enrolled 2478 participants, of whom 1422 (57%) had COVID-19. The prevalence of symptoms at 6 weeks was 26% (n = 373) in those with COVID-19 and 18% (n = 195) in those without COVID-19. Fatigue (11%) and difficulty sleeping (7%) were most strongly associated with COVID-19. A total of 1643 (66%) participants received a subsequent vaccine dose (after the primary series). Participants with COVID-19 who had received a subsequent vaccination had lower odds of symptoms at 6 weeks (adjusted odds ratio [aOR], 0.55; 95% CI, 0.43–0.70), but this relationship was not observed in those without COVID-19 (aOR, 0.87; 95% CI, 0.59–1.29). Conclusions: Health care personnel who received subsequent doses of original monovalent COVID-19 vaccine had a lower prevalence of symptoms at 6 weeks than those that did not.
- Open Access
- 21 May 2024
- Published by Cambridge University Press (CUP) in Infection Control & Hospital Epidemiology
- Vol. 45 (9) , 1090-1098
Characteristics of healthcare personnel with SARS-CoV-2 infection: 10 emerging infections program sites in the United States, April 2020–December 2021
Background: Understanding characteristics of healthcare personnel (HCP) with SARS-CoV-2 infection supports the development and prioritization of interventions to protect this important workforce. We report detailed characteristics of HCP who tested positive for SARS-CoV-2 from April 20, 2020 through December 31, 2021.Methods: CDC collaborated with Emerging Infections Program sites in 10 states to interview HCP with SARS-CoV-2 infection (case-HCP) about their demographics, underlying medical conditions, healthcare roles, exposures, personal protective equipment (PPE) use, and COVID-19 vaccination status. We grouped case-HCP by healthcare role. To describe residential social vulnerability, we merged geocoded HCP residential addresses with CDC/ATSDR Social Vulnerability Index (SVI) values at the census tract level. We defined highest and lowest SVI quartiles as high and low social vulnerability, respectively.Results: Our analysis included 7,531 case-HCP. Most case-HCP with roles as certified nursing assistant (CNA) (444, 61.3%), medical assistant (252, 65.3%), or home healthcare worker (HHW) (225, 59.5%) reported their race and ethnicity as either non-Hispanic Black or Hispanic. More than one third of HHWs (166, 45.2%), CNAs (283, 41.7%), and medical assistants (138, 37.9%) reported a residential address in the high social vulnerability category. The proportion of case-HCP who reported using recommended PPE at all times when caring for patients with COVID-19 was lowest among HHWs compared with other roles.Conclusions: To mitigate SARS-CoV-2 infection risk in healthcare settings, infection prevention, and control interventions should be specific to HCP roles and educational backgrounds. Additional interventions are needed to address high social vulnerability among HHWs, CNAs, and medical assistants.
- 21 May 2024
- Published by Cambridge University Press (CUP) in Infection Control & Hospital Epidemiology
- Vol. 45 (9) , 1090-1098
Open AccessCharacteristics of healthcare personnel with SARS-CoV-2 infection: 10 emerging infections program sites in the United States, April 2020–December 2021
Background: Understanding characteristics of healthcare personnel (HCP) with SARS-CoV-2 infection supports the development and prioritization of interventions to protect this important workforce. We report detailed characteristics of HCP who tested positive for SARS-CoV-2 from April 20, 2020 through December 31, 2021.Methods: CDC collaborated with Emerging Infections Program sites in 10 states to interview HCP with SARS-CoV-2 infection (case-HCP) about their demographics, underlying medical conditions, healthcare roles, exposures, personal protective equipment (PPE) use, and COVID-19 vaccination status. We grouped case-HCP by healthcare role. To describe residential social vulnerability, we merged geocoded HCP residential addresses with CDC/ATSDR Social Vulnerability Index (SVI) values at the census tract level. We defined highest and lowest SVI quartiles as high and low social vulnerability, respectively.Results: Our analysis included 7,531 case-HCP. Most case-HCP with roles as certified nursing assistant (CNA) (444, 61.3%), medical assistant (252, 65.3%), or home healthcare worker (HHW) (225, 59.5%) reported their race and ethnicity as either non-Hispanic Black or Hispanic. More than one third of HHWs (166, 45.2%), CNAs (283, 41.7%), and medical assistants (138, 37.9%) reported a residential address in the high social vulnerability category. The proportion of case-HCP who reported using recommended PPE at all times when caring for patients with COVID-19 was lowest among HHWs compared with other roles.Conclusions: To mitigate SARS-CoV-2 infection risk in healthcare settings, infection prevention, and control interventions should be specific to HCP roles and educational backgrounds. Additional interventions are needed to address high social vulnerability among HHWs, CNAs, and medical assistants.